European Industry Voices Concern As Products Vanish From Market
Fresh Data On European Generics Has Exposed The Fragility Of The Supply Network
Executive Summary
A fresh report has offered stark new data on the extent to which generics are disappearing from the European market. Industry association Medicines for Europe has pointed to the risks of supply consolidation, urging both national- and EU-level action.
You may also be interested in...
EU Reforms Offer Mixed Blessings For Generics And Biosimilars
A long-awaited package of European pharmaceutical legislation reforms unveiled by the European Commission contains a number of measures that will affect the generics and biosimilars industry – including changes to regulatory data protection periods, simplified marketing authorization procedures, and moves towards greater digitalization.
EU Reforms Offer Mixed Blessings For Generics And Biosimilars
A long-awaited package of European pharmaceutical legislation reforms unveiled by the European Commission contains a number of measures relating to generics and biosimilars – including changes to regulatory data protection periods, simplified marketing authorization procedures and moves towards greater digitalization.
Industry Speaks Out On Global Antibiotics Shortages
Responding to shortages of antibiotics seen around the world, the IGBA has insisted that the generics industry is working to address spikes in demand and has set out a series of recommendations to mitigate the situation. Meanwhile, US association the AAM has countered suggestions that supply issues are due to a “broken generic drug market.”